Poly ethylene glycol methyl ether peg

Phosphatidylserine (PS) was purchased from Shanghai Yiji Medicine & Chemical Co, Ltd. Boc-NH-PEG-COO-NHS, Poly-(ethylene glycol) methyl ether (PEG, Mn = 2000), Rb (rhodamine b) and CaCl₂ were obtained from Sigma-Aldrich, and RGD was purchased from Corner Stone Therapeutics (Shanghai), Ltd (Shanghai, China).
VRP was purchased from Melonepharma Co, Ltd, Dalian. NVT was purchased from Chongqing Carelife Pharmaceutical Co, Ltd. (NH₄)₂HPO₄ was obtained from Sinopharm Chemical Reagent Co., Ltd.
MCF7/MDR cells (MDR human breast cancer cells) and MCF7 cells were obtained from the Institute of Biochemistry and Cell Biology at the Chinese Academy of Sciences (Shanghai, China). BALB/c nude mice were provided from the Animal Experiment Centre of Shanghai Cancer Institute.

PEO M_w = 5 × 10⁶ g·mol⁻¹ from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA) was used to prepare the composites. LiTFSI, from Aldrich and neat sepiolite, kindly supplied by TOLSA S.A. (TOLSA, Madrid, Spain), were dried under a vacuum for 24 h. d-α-tocopherol polyethylene glycol 1000 succinate (TPGS), used to prepare the modified sepiolite TPGS–S, was purchased from Aldrich and used as received. Details on the preparation of TPGS-S have appeared elsewhere [14 (link)]. The RTILs employed to prepare the electrolytes listed in Table 1 were purchased from Solvionic (Solvionic, Toulouse, France), all of them with 99.5% purity. They are the following: 1-ethyl-3-methylimidazolium bis(fluorosulfonyl)imide (EMIFSI), N-propyl-N-methylpyrrolidinium bis(fluorosulfonyl)imide (PMPFSI); N-propyl-N-methylpyrrolidinium bis(trifluoromethanesulfonyl)imide (PMPTFSI), 1-ethyl-3-methylimidazolium bis(trifluoromethanesulfonyl) imide (EMITFSI).
Solutions of LiTFSI with RTILs and poly(ethylene glycol) methyl ether (PEG), M_n = 550 g·mol⁻¹ from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA) were prepared by magnetic stirring for 30–120 min, as model liquid phases for the solid polymer electrolytes.